Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Metadata
Title
Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors
Authors
Angela Mercy Ralte
Mehar Chand Sharma
Asis Kumar Karak
Veer Singh Mehta
Chitra Sarkar
Publication date
01-12-2001
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2001
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/BF03032383

Other articles of this Issue 4/2001

Pathology & Oncology Research 4/2001 Go to the issue

Article

MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma

Case Report

Clot retention and spontaneous rupture with secondary pneumatosis of bladder wall following routine cystoscopy

Article

Limitations of fine-needle aspiration cytology to diagnose metaplastic carcinoma of the breast

Article

Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma

Review

The role of boost irradiation in the conservative treatment of stage I-II breast cancer

Article

Expression of a decorin-like molecule in human melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits